Heritage — Inherited risk, for you and your family.
Where Signature reads the tumour, Heritage reads you.
Heritage is OnKommon's hereditary-cancer service. Where Signature reads the tumour, Heritage reads you — the inherited (germline) changes you were born with that can raise cancer risk for you and your blood relatives. It answers a different, deeply human question: is this cancer part of a pattern the family should know about, and can we act to protect the people you love?
One test can protect a whole family.
Heritage identifies inherited risk — and gives you the time to prevent it. For you, for your children, for your siblings.
- For you: Inherited changes can shape treatment and future screening
- For your family: Identifying a variant lets relatives choose testing, earlier screening, and prevention
- For prevention: Knowing risk in advance turns cancer care from reactive to proactive
- Genetic counselling included: Before and after — you are never handed a life-changing result alone
Three reasons to know your inherited risk.
Heritage answers the questions that affect not just you, but everyone who shares your blood.
For You
An inherited change can shape treatment — some cancers with germline changes respond to specific drugs — and guide your future screening plan.
For Your Family
Identifying a variant lets relatives choose testing, earlier screening, and prevention. One test can protect a whole family.
For Prevention
Knowing risk in advance turns cancer care from reactive to proactive. You gain the time to prevent, not just treat.
Choose the right test for your situation.
Whether you need a full assessment or targeted cascade testing — Heritage has the right option.
Heritage Core
- Best when: You want a full inherited-risk assessment
- Who it helps: You and, through you, your family
- Price: ₹50,000 index test
Heritage Adhoc
- Best when: A family variant is already known (cascade testing)
- Who it helps: Relatives of someone with a known variant
- Price: ₹35,000 per additional family member
No result without support.
Inherited risk is sensitive — it touches family, children, and difficult feelings. Every Heritage test includes genetic counselling through KPCIRC, before and after.
Before Testing
To help you decide what you want to know — what the test can and cannot tell you, and what it means for your family.
After Testing
To explain results in plain language, and to plan next steps for you and your family — in the language you are most comfortable with.
Ongoing Support
You are never handed a life-changing result and left alone with it. Your genetic counsellor is there for you and your family.
Transparent pricing for you and your family.
The index test is ₹50,000. Cascade testing for relatives — checking for the specific variant found — is ₹35,000 per family member.
The words you will see, in plain language.
What we DO
- Assess inherited (germline) cancer risk for you
- Enable cascade testing to protect blood relatives
- Include KPCIRC genetic counselling before and after
- Flag inherited changes that can shape treatment
What we DON'T do
- Diagnose cancer or read the tumour (that is Signature)
- Predict with certainty that a cancer will occur
- Test relatives without their own consent and counselling
- Replace clinical screening or your specialist's advice
Heritage tests are genomic (DNA-based) tests offered for use by qualified healthcare professionals. They are intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →Heritage — Overview
PILLAR 3 · INHERITED RISK, FOR YOU AND YOUR FAMILY
Heritage is OnKommon's hereditary-cancer service. Where Signature reads the tumour, Heritage reads you — the inherited (germline) changes you were born with that can raise cancer risk for you and your blood relatives. It answers a different, deeply human question: is this cancer part of a pattern the family should know about, and can we act to protect the people you love?
Decoder · germline vs somatic
Germline changes are inherited — present in every cell from birth, and passable to children. They explain hereditary cancer risk and can be found from a blood or saliva sample. Somatic changes arise in the tumour during life and are not inherited. Heritage looks at germline (inherited) risk; Signature looks at the somatic tumour. Both matter, for different reasons.
2 · Why it matters
Heritage answers the questions that affect not just you, but everyone who shares your blood.
For you
An inherited change can shape treatment (some cancers with germline changes respond to specific drugs) and future screening.
For your family
Identifying a variant lets relatives choose testing, earlier screening, and prevention. One test can protect a whole family.
For prevention
Knowing risk in advance turns cancer care from reactive to proactive.
3 · The two Heritage tests
Choose the right test for your situation.
Heritage Core
- What it is: A broad hereditary‑cancer panel
- Best when: You want a full inherited‑risk assessment
- Who it helps: You and, through you, your family
Heritage Adhoc
- What it is: A focused test for a specific known variant
- Best when: A family variant is already known (cascade testing)
- Who it helps: Relatives of someone with a known variant
4 · Genetic counselling is included
No result without support
Before testing
To help you decide what you want to know
After testing
To explain results in plain language
Ongoing
To plan next steps for you and your family
5 · Pricing
₹50,000 index test · ₹35,000 per additional family member
RESEARCH & EVIDENCE
The science behind this
Heritage uses multi‑gene germline panels — an approach that repeatedly finds inherited risk that would otherwise be missed.
Study 1 · Inherited risk is common — and often unexpected
Among 10,975 cancer patients tested with a broad germline panel, 10.3% carried a pathogenic variant in a cancer‑susceptibility gene, and many would not have been predicted from personal or family history alone.
Study 2 · Panels find actionable variants across the board
In a large colorectal‑cancer cohort, 14.2% carried a pathogenic germline variant, with clinically actionable findings across every age, ancestry and panel size.
Study 3 · Guideline criteria miss carriers
When testing is restricted to guideline criteria, roughly half of patients who carry a pathogenic variant can be missed — an argument for broader testing.
These independent, peer‑reviewed studies describe the class of technology OnKommon uses. They are shared for education; they are not results for any individual and are not a promise of benefit.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
TRANSPARENCY — WHAT WE DO AND DON’T
Being clear about our limits
What we DO
- Assess inherited (germline) cancer risk for you
- Enable cascade testing to protect blood relatives
- Include KPCIRC genetic counselling before and after
- Flag inherited changes that can shape treatment
What we DON'T do
- Diagnose cancer or read the tumour (that is Signature)
- Predict with certainty that a cancer will occur
- Test relatives without their own consent and counselling
- Replace clinical screening or your specialist's advice
Heritage tests is a genomic (DNA‑based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A “not detected” or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample‑collection kits are for use by qualified phlebotomists only — not for self‑testing or self‑sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in‑vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP‑accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE‑IVD certified variant database. The OnKommon interpretation engine is provided for research and decision‑support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Need a second opinion or professional feedback?
If you want an independent clinical view — or you are a clinician seeking a molecular tumour board discussion — our exclusive clinical partner KPCIRC provides paid second opinions, molecular tumour board reviews, and genetic counselling. Ask your navigator, or request it from any page.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
1 Book a free Blueprint Consultation
A no‑obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →3 Free WhatsApp guidance (Signal)
A 4‑hour triage reply to your first question, at no cost.
Start WhatsApp triage →